<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Quality Measures Clearinghouse (NQMC).</xmlsource><Section SecID="560" OrdBy="10" Name="General"><Field FieldID="11" OrdBy="20" ID="561" Name="Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Chronic kidney disease (CKD): the percentage of patients on the CKD register with hypertension and proteinuria who are currently treated with an ACE-I or ARB.&lt;/div&gt;" /></Field><Field FieldID="1" OrdBy="30" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); Proteinuria  (791.0)"/><FieldValue Value="MSH: Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Hypertension ; Kidney Diseases ; Proteinuria ; Registries ; Renal Insufficiency, Chronic "/><FieldValue Value="MTH: Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Chronic kidney disease stage 5 ; Chronic Kidney Diseases ; Chronic Kidney Insufficiency ; Hypertensive disease ; Kidney Diseases ; Proteinuria ; Registries "/><FieldValue Value="SNOMEDCT_US: Angiotensin-converting enzyme inhibitor agent ; Chronic kidney disease stage 3 ; Chronic kidney disease stage 4 ; Chronic kidney disease stage 5 ; Chronic renal impairment ; Hypertensive disorder ; Kidney disease ; Proteinuria "/></Field></Section><Section SecID="563" OrdBy="40" Name="Measure Domain"><Field FieldID="3025" OrdBy="50" ID="564" Name="Primary Measure Domain" Type="picklist-one"><FieldValue Value="Clinical Quality Measures: Process" /></Field><Field FieldID="3026" OrdBy="60" ID="565" Name="Secondary Measure Domain" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field></Section><Section SecID="566" OrdBy="70" Name="Brief Abstract"><Field FieldID="34" OrdBy="80" ID="567" Name="Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure is used to assess the percentage of patients on the chronic kidney disease (CKD) register with hypertension and proteinuria who are currently treated with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="21" OrdBy="90" ID="568" Name="Rationale" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The international classification developed by the United States (U.S.) National Kidney Foundation describes five stages of chronic kidney disease (CKD) using an estimated glomerular filtration rate (eGFR) to measure kidney function (see Table 3 in the original measure documentation). Patients with CKD stage 3 to stage 5 have, by definition, less than 60 per cent of their kidney function. Stage 3 is a moderate decrease in glomerular filtration rate (GFR) with or without other evidence of kidney damage. Several groups (National Institute for Health and Care Excellence [NICE], Scottish Intercollegiate Guidelines Network [SIGN], United Kingdom [UK] Consensus) have recommended splitting stage 3 into 3A and 3B (see Table 3 in the original measure documentation). Stage 4 is a severe decrease in GFR with or without other evidence of kidney damage and stage 5 is established renal failure. This indicator set refers to patients with stage 3 to stage 5 CKD.&lt;/p&gt;&#xA;&lt;p&gt;CKD is a long-term condition; the most recent population data from the National Health and Nutrition Examination Survey (NHANES 1999-2004) suggests that the age standardised prevalence of stage 3 to 5 CKD in the non-institutionalised American population is approximately six per cent (Coresh et al., 2007) The prevalence in females was higher than in males (6.9 per cent versus 4.9 per cent). In the fully adjusted model, the prevalence of low GFR was strongly associated with diagnosed diabetes (odds ratio [OR], 1.54; 95 per cent confidence interval [CI], 1.28-180) and hypertension (OR, 1.98; 95 per cent CI, 1.73-2.67) as well as higher body mass index (BMI) (OR, 1.08; 95 per cent CI, 1.02-1.15 per 5-unit increment of BMI).&lt;/p&gt;&#xA;&lt;p&gt;In the UK the prevalence of CKD stage 3 to 5 was 8.5 per cent and was higher in females, 10.6 per cent in females versus 5.8 per cent in males (Stevens et al., 2007). The Association of Public Health Observatories (APHO) (Morgan, 2009) has modelled the prevalence of CKD for England and Wales based on the results of the study by Stevens et al and report a population prevalence of 8.9 per cent.&lt;/p&gt;&#xA;&lt;p&gt;Refer to the National Service Framework (NSF) for Renal Services (2005) for further information.&lt;/p&gt;&#xA;&lt;p&gt;This indicator set applies to patients with stage 3, 4 and 5 CKD (eGFR&amp;lt;60 mL/min/1.73 m&amp;sup2; confirmed with at least two separate readings over a three month period).&lt;/p&gt;&#xA;&lt;p&gt;CKD may be progressive; prevalence increases with age and female sex but progression increases with male sex, and South Asian and African Caribbean ethnicity. People of South Asian origin are particularly at risk of having both diabetes and CKD. Diabetes is more common in this community than in the population overall. People of African and African Caribbean origin have an increased risk of CKD progression linked to hypertension.&lt;/p&gt;&#xA;&lt;p&gt;Only a minority of patients with stage 1 or 2 CKD go on to develop more advanced disease and symptoms do not usually appear until stage 4. Where eGFR has persistently been recorded below 60 the CKD (stage 3) label continues to apply, even if future management may lead to an improvement in eGFR.&lt;/p&gt;&#xA;&lt;p&gt;Early identification of CKD is important as it allows appropriate measures to be taken not only to slow or prevent the progression to more serious CKD but also to combat the major risk of illness or death due to cardiovascular disease (CVD). The presence of proteinuria is a key risk multiplier at all stages of CKD and CKD is an independent risk factor for CVD and a multiplier of other risk factors (Wali &amp;amp; Henrich, 2005).&lt;/p&gt;&#xA;&lt;p&gt;Refer to NICE clinical guideline 73, &quot;Early identification and management of chronic kidney disease in adults in primary and secondary care&quot; (2008), and SIGN guideline 103, &quot;Diagnosis and management of CKD in adults&quot; (2008), for further information.&lt;/p&gt;&#xA;&lt;p&gt;These indicators reflect both of the guidance documents.&lt;/p&gt;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xA;    &lt;li&gt;Albumin:creatinine ratio (ACR) is the preferred measure of proteinuria. &lt;/li&gt;&#xA;    &lt;li&gt;NICE suggests blood pressure (BP) is kept below 140 (systolic) and 90 (diastolic) with a target for systolic of between 120 and 139 mmHg. There is a tougher standard for diabetes. This compares with a blood pressure audit standard of 145/85 mmHg in this guidance for 40 to 70 per cent of the CKD population. &lt;/li&gt;&#xA;    &lt;li&gt;NICE recommends that the use of angiotensin-converting enzyme inhibitors (ACE-I) when there is hypertension and an ACR of &amp;ge;30 mg/mmol. However, when ACR &amp;ge;70 mg/mmol NICE recommends ACE-I even in the absence of hypertension. As with BP there are stricter standards in diabetes. &lt;/li&gt;&#xA;    &lt;li&gt;NICE divides stage 3 into stage 3a and 3b. NICE recommends testing for bone disease and anaemia in stage 3b (eGFR 30 to 44), as well as stages 4 and 5. &lt;/li&gt;&#xA;    &lt;li&gt;NICE also recommends addition of the suffix (p) to denote significant proteinuria, defined as an ACR &amp;ge;30 mg/mmol (protein:creatinine ratio [PCR] &amp;ge;50 mg/mmol). &lt;/li&gt;&#xA;&lt;/ol&gt;&#xA;&lt;p&gt;ACE-I and angiotensin receptor blockers (ARBs) are generally more effective than other anti-hypertensives in minimising deterioration in kidney function and this effect is most marked where there is significant proteinuria. Such treatment is both clinically and cost-effective (Kent et al., 2007; Lewis et al., 1993; Brenner et al., 2001; Ruggenenti et al., 1999).&lt;/p&gt;&#xA;&lt;p&gt;The gold standard test for measuring proteinuria is a 24-hour urine collection; though problems with timing and completeness make this an impractical test to use in general practice. The alternatives are to test the ACR or PCR in the urine or to use a stick test.&lt;/p&gt;&#xA;&lt;p&gt;The SIGN clinical guideline on CKD (2008) recommends measuring proteinuria with ACR in patients with diabetes and total protein:creatinine ratio (TPCR) in non-diabetic patients, reflecting the differing evidence base for these two patient populations whereas recent the NICE clinical guideline on CKD (2008) suggests that the ACR be used in all patients.&lt;/p&gt;&#xA;&lt;p&gt;Therefore, patients who are non-diabetic stage 3 to 5 CKD should have an annual test of proteinuria ideally using ACR, or PCR according to local guidance. Patients with diabetes already have an annual micro-albuminuria test.&lt;/p&gt;&#xA;&lt;p&gt;A systematic review has shown that investigation for infection of asymptomatic patients with one &quot;+&quot; or more is not indicated (Carter et al., 2006). It is advised that practitioners only send a midstream urine sample or perform another test to look for infection if there are symptoms.&lt;/p&gt;&#xA;&lt;p&gt;It is not possible to derive a simple correct factor that allows the conversion of ACR values to PCR or 24-hour urinary protein excretion rates because the relative amounts of albumin and other proteins will vary depending on the clinical circumstances; however, the following table of approximate equivalents will allow clinicians unfamiliar with ACR values to see the approximate equivalent PCR and 24-hour urinary protein excretion rates.&lt;/p&gt;&#xA;&lt;table width=&quot;70%&quot; align=&quot;center&quot; border=&quot;1&quot; cellspacing=&quot;0&quot; cellpadding=&quot;5&quot; summary=&quot;Approximate equivalent ACR/PCR and 24 hour urinary protein excretion&quot;&gt;&#xA;    &lt;tbody&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;ACR (mg/mmol)&lt;/th&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;PCR (mg/mmol)&lt;/th&gt;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;24 Hour Urinary Protein &lt;br /&gt;&#xA;            Excretion (g/day)&lt;/th&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/tbody&gt;&#xA;    &lt;tbody&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;30&lt;/td&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;50&lt;/td&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;0.5&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;        &lt;tr&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;70&lt;/td&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;100&lt;/td&gt;&#xA;            &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;1&lt;/td&gt;&#xA;        &lt;/tr&gt;&#xA;    &lt;/tbody&gt;&#xA;&lt;/table&gt;&lt;/div&gt;" /></Field><Field FieldID="3500" OrdBy="100" ID="569" Name="Evidence for Rationale" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001 Sep 20;345(12):861-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11565518&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Carter JL, Tomson CR, Stevens PE, Lamb EJ. Does urinary tract infection cause proteinuria or microalbuminuria? A systematic  review. Nephrol Dial Transplant. 2006 Nov;21(11):3031-7. [67 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16861738&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, Van Lente F, Levey AS. Prevalence of chronic kidney disease in the United States. JAMA. 2007 Nov 7;298(17):2038-47. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17986697&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, de Zeeuw D, Remuzzi G, Kamper AL, Levey AS. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007 Jun;18(6):1959-65. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17475813&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993 Nov 11;329(20):1456-62. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8413456&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Morgan T, Eastern Region Public Health Observatory (ERPHO), Association of Public Health Observatories (APHO). Estimated prevalence of chronic kidney disease (CKD) stages 3-5 by age group in males, females and total persons (18 +). London (UK): Public Health England (PHE); 2009 Jan 21. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;National Collaborating Centre for Chronic Conditions. Chronic kidney disease. Early identification and management of chronic kidney disease in adults in primary and secondary care. London (UK): National Institute for Health and Clinical Excellence (NICE); 2008 Sep. 36 p.&amp;nbsp;(Clinical guideline; no. 73).&amp;nbsp;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999 Jul 31;354(9176):359-64. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10437863&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of chronic kidney disease. A national clinical guideline. Edinburgh (Scotland): Scottish Intercollegiate Guidelines Network (SIGN); 2008. 50 p.&amp;nbsp;(SIGN publication; no. 103).&amp;nbsp; [250 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Stevens PE, O'Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B, Middleton R, Hague N, New J, Farmer CK. Chronic kidney disease management in the United Kingdom: NEOERICA project results. Kidney Int. 2007 Jul;72(1):92-9. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17440495&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Wali RK, Henrich WL. Chronic kidney disease: a risk factor for cardiovascular disease. Cardiol Clin. 2005 Aug;23(3):343-62. [120 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16084283&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="3022" OrdBy="110" ID="570" Name="Primary Health Components" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Chronic kidney disease (CKD); hypertension; proteinuria; angiotensin-converting enzyme inhibitor (ACE-I); angiotensin receptor blocker (ARB)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="23" OrdBy="120" ID="571" Name="Denominator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients who are on the chronic kidney disease (CKD) register with hypertension and proteinuria (see the related &quot;Denominator Inclusions/Exclusions&quot; field)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="24" OrdBy="130" ID="572" Name="Numerator Description" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Number of patients from the denominator who are currently treated with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB) &lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="573" OrdBy="140" Name="Evidence Supporting the Measure"><Field FieldID="3027" OrdBy="150" ID="574" Name="Type of Evidence Supporting the Criterion of Quality for the Measure" Type="picklist-choice"><FieldValue Value="A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence" /><FieldValue Value="A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences" /><FieldValue Value="One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal" /></Field><Field FieldID="3501" OrdBy="160" ID="575" Name="Additional Information Supporting Need for the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3072" OrdBy="180" ID="577" Name="Extent of Measure Testing" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="580" OrdBy="210" Name="State of Use of the Measure"><Field FieldID="3029" OrdBy="220" ID="581" Name="State of Use" Type="picklist-one"><FieldValue Value="Current routine use" /></Field><Field FieldID="3030" OrdBy="230" ID="582" Name="Current Use" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field></Section><Section SecID="583" OrdBy="240" Name="Application of the Measure in its Current Use"><Field FieldID="3031" OrdBy="250" ID="584" Name="Measurement Setting" Type="picklist-choice"><FieldValue Value="Ambulatory/Office-based Care" /></Field><Field FieldID="3032" OrdBy="260" ID="585" Name="Professionals Involved in Delivery of Health Services" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3033" OrdBy="270" ID="586" Name="Least Aggregated Level of Services Delivery Addressed" Type="picklist-one"><FieldValue Value="Clinical Practice or Public Health Sites" /></Field><Field FieldID="3505" OrdBy="280" ID="587" Name="Statement of Acceptable Minimum Sample Size" Type="picklist-one"><FieldValue Value="Unspecified" /></Field><Field FieldID="41" OrdBy="290" ID="588" Name="Target Population Age" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Age greater than or equal to 18 years&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="42" OrdBy="300" ID="589" Name="Target Population Gender" Type="picklist-one"><FieldValue Value="Either male or female" /></Field></Section><Section SecID="660" OrdBy="310" Name="National Strategy for Quality Improvement in Health Care"><Field FieldID="3522" OrdBy="320" ID="661" Name="National Quality Strategy Aim" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Better Care&lt;/li&gt;&lt;/ul&gt;" /></Field><Field FieldID="3525" OrdBy="330" ID="662" Name="National Quality Strategy Priority" Type="text"><FieldValue Value="&lt;ul&gt;&lt;li&gt;Prevention and Treatment of Leading Causes of Mortality&lt;/li&gt;&lt;/ul&gt;" /></Field></Section><Section SecID="590" OrdBy="340" Name="Institute of Medicine (IOM) National Health Care Quality Report Categories"><Field FieldID="3163" OrdBy="350" ID="591" Name="IOM Care Need" Type="picklist-choice"><FieldValue Value="Living with Illness" /></Field><Field FieldID="3164" OrdBy="360" ID="592" Name="IOM Domain" Type="picklist-choice"><FieldValue Value="Effectiveness" /></Field></Section><Section SecID="593" OrdBy="370" Name="Data Collection for the Measure"><Field FieldID="3506" OrdBy="380" ID="594" Name="Case Finding Period" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The reporting year&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3054" OrdBy="390" ID="595" Name="Denominator Sampling Frame" Type="picklist-one"><FieldValue Value="Patients associated with provider" /></Field><Field FieldID="3057" OrdBy="400" ID="598" Name="Denominator (Index) Event or Characteristic" Type="picklist-choice"><FieldValue Value="Clinical Condition" /><FieldValue Value="Patient/Individual (Consumer) Characteristic" /></Field><Field FieldID="3058" OrdBy="410" ID="599" Name="Denominator Time Window" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="55" OrdBy="420" ID="596" Name="Denominator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Patients who are on the chronic kidney disease (CKD) register with hypertension and proteinuria&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The register includes patients aged 18 years or over with CKD (United States [U.S.] National Kidney Foundation: Stage 3 to 5 CKD).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: Exception reporting applies to indicators in any domain of the Quality and Outcomes Framework (QOF), where the achievement is determined by the percentage of patients receiving the specified level of care.&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&quot;Exceptions&quot; relate to registered patients who are on the relevant disease register or in the target population group and would ordinarily be included in the indicator denominator, but who are excepted by the contractor on the basis of one or more of the exception criteria. Patients are removed from the denominator and numerator for an indicator if they have been both excepted and they have not received the care specified in the indicator wording. If the patient has been excepted but subsequently the care has been carried out within the relevant time period, the patient will be included in both the denominator and the numerator (achievement will always override an exception).&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Patients may be excepted if they fall within the strict criteria detailed below:&lt;/p&gt;&#xD;&#xA;&lt;ol class=&quot;Note&quot; style=&quot;list-style-type: upper-alpha;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients who have been recorded as refusing to attend review who have been invited on at least three occasions during the financial year to which the achievement payments relate (except in the case of indicator CS002, where the patient should have been invited on at least three occasions during the period of time specified in the indicator during which achievement is to be measured [e.g., the preceding five years ending on 31 March in the financial year to which achievement payments relate]). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom it is not appropriate to review the chronic disease parameters due to particular circumstances, for example, a patient who has a terminal illness or is extremely frail. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients newly diagnosed or who have recently registered with the contractor who should have measurements made within three months and delivery of clinical standards within nine months, e.g., blood pressure or cholesterol measurements within target levels. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients who are on maximum tolerated doses of medication whose levels remain sub-optimal. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients for whom prescribing a medication is not clinically appropriate, e.g., those who have an allergy, contraindication or have experienced an adverse reaction. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient has not tolerated medication. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where a patient does not agree to investigation or treatment (informed dissent) and this has been recorded in their patient record following a discussion with the patient. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where the patient has a supervening condition which makes treatment of their condition inappropriate, e.g., cholesterol reduction where the patient has liver disease. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where an investigative service or secondary care service is unavailable. &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;Refer to the original measure documentation for further details.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3507" OrdBy="430" ID="597" Name="Exclusions/Exceptions" Type="picklist-choice-4"><FieldValue Value="not defined yet" /></Field><Field FieldID="59" OrdBy="440" ID="600" Name="Numerator Inclusions/Exclusions" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Inclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Number of patients from the denominator who are currently treated with an angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin receptor blocker (ARB)&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Exclusions&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3061" OrdBy="450" ID="601" Name="Numerator Search Strategy" Type="picklist-one"><FieldValue Value="Fixed time period or point in time" /></Field><Field FieldID="3062" OrdBy="460" ID="602" Name="Data Source" Type="picklist-many"><FieldValue Value="Electronic health/medical record" /><FieldValue Value="Paper medical record" /><FieldValue Value="Registry data" /></Field><Field FieldID="3065" OrdBy="470" ID="603" Name="Type of Health State" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3066" OrdBy="480" ID="604" Name="Instruments Used and/or Associated with the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="605" OrdBy="490" Name="Computation of the Measure"><Field FieldID="3508" OrdBy="500" ID="606" Name="Measure Specifies Disaggregation" Type="picklist-one"><FieldValue Value="Does not apply to this measure" /></Field><Field FieldID="3067" OrdBy="520" ID="608" Name="Scoring" Type="picklist-many"><FieldValue Value="Rate/Proportion" /></Field><Field FieldID="3068" OrdBy="530" ID="609" Name="Interpretation of Score" Type="picklist-one"><FieldValue Value="Desired value is a higher score" /></Field><Field FieldID="3090" OrdBy="540" ID="610" Name="Allowance for Patient or Population Factors" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="3070" OrdBy="560" ID="612" Name="Standard of Comparison" Type="picklist-choice-3"><FieldValue Value="not defined yet" /></Field><Field FieldID="71" OrdBy="570" ID="613" Name="Prescriptive Standard" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Achievement thresholds: 45% to 80%&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="9" OrdBy="580" ID="614" Name="Evidence for Prescriptive Standard" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="615" OrdBy="590" Name="Identifying Information"><Field FieldID="73" OrdBy="600" ID="616" Name="Original Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;CKD003. The percentage of patients on the CKD register with hypertension and proteinuria who are currently treated with an ACE-I or ARB.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="74" OrdBy="610" ID="617" Name="Measure Collection Name" Type="text"><FieldValue Value="Quality and Outcomes Framework Indicators" /></Field><Field FieldID="75" OrdBy="620" ID="618" Name="Measure Set Name" Type="text"><FieldValue Value="Chronic Kidney Disease (CKD)" /></Field><Field FieldID="16" OrdBy="650" ID="621" Name="Submitter" Type="orglist"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="17" OrdBy="660" ID="622" Name="Developer" Type="orglist-p"><FieldValue Value="British Medical Association - Medical Specialty Society" /><FieldValue Value="National Health Service (NHS) Confederation - National Government Agency [Non-U.S.]" /></Field><Field FieldID="79" OrdBy="670" ID="623" Name="Funding Source(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The expert panel who developed the indicators were funded by the English Department of Health.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="80" OrdBy="680" ID="624" Name="Composition of the Group that Developed the Measure" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The main indicator development group is based in the National Primary Care Research and Development Centre in the University of Manchester. They are: Professor Helen Lester, NPCRDC, MB, BCH, MD; Dr. Stephen Campbell, NPCRDC, PhD; Dr. Umesh Chauhan, NPCRDC, MB, BS, PhD.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Others involved in the development of individual indicators are: Professor Richard Hobbs, Dr. Richard McManus, Professor Jonathan Mant, Dr. Graham Martin, Professor Richard Baker, Dr. Keri Thomas, Professor Tony Kendrick, Professor Brendan Delaney, Professor Simon De Lusignan, Dr. Jonathan Graffy, Dr. Henry Smithson, Professor Sue Wilson, Professor Claire Goodman, Dr. Terry O'Neill, Dr. Philippa Matthews, Dr. Simon Griffin, Professor Eileen Kaner.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="81" OrdBy="690" ID="625" Name="Financial Disclosures/Other Potential Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None for the main indicator development group.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="82" OrdBy="700" ID="626" Name="Endorser" Type="orglist"><FieldValue Value="National Health Service - National Government Agency [Non-U.S.]" /></Field><Field FieldID="19" OrdBy="730" ID="629" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This measure was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3086" OrdBy="740" ID="630" Name="Date of Most Current Version in NQMC" Type="date"><FieldValue Value="2014 Mar" /></Field><Field FieldID="3511" OrdBy="750" ID="631" Name="Measure Maintenance" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="3512" OrdBy="760" ID="632" Name="Date of Next Anticipated Revision" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Unspecified&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="20" OrdBy="770" ID="633" Name="Measure Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the measure.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This measure updates a previous version: British Medical Association (BMA) and NHS Employers. Quality and outcomes framework guidance for GMS contract 2013/14. London (UK): British Medical Association, National Health Service Confederation; 2013 Mar. 203 p. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="14" OrdBy="780" ID="634" Name="Measure Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The individual measure, &quot;CKD003. The Percentage of Patients on the CKD Register with Hypertension and Proteinuria Who Are Currently Treated with an ACE-I or ARB,&quot; is published in the &quot;2014/15 General Medical Services (GMS) Contract Quality and Outcomes Framework (QOF): Guidance for GMS Contract 2014/15.&quot; This document is available from the &lt;a href=&quot;http://bma.org.uk/-/media/files/pdfs/practical%20advice%20at%20work/contracts/gpqofguidance2014-15.pdf&quot; title=&quot;BMA Web site&quot;&gt;British Medical Association Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="87" OrdBy="800" ID="636" Name="NQMC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NQMC summary was completed by ECRI on November 14, 2006. The information was verified by the measure developer on November 29, 2006. &lt;/p&gt;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on January 28, 2009 and on October 1, 2009. The information was verified by the measure developer on March 4, 2010. &lt;/p&gt;&#xA;&lt;p&gt;This NQMC summary was retrofitted into the new template on June 27, 2011. &lt;/p&gt;&#xA;&lt;p&gt;This NQMC summary was updated by ECRI Institute on October 11, 2013 and again on September 12, 2014. &lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="88" OrdBy="810" ID="637" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;No copyright restrictions apply.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="641" OrdBy="850" Name="Production"><Field FieldID="1" OrdBy="1366" ID="562" Name="Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;British Medical Association (BMA) and NHS Employers. 2014/15 general medical services (GMS) contract quality and outcomes framework (QOF): guidance for GMS contract 2014/15. London (UK): British Medical Association, National Health Service Confederation; 2014 Mar. 182 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NQMC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Quality Measures Clearinghouseâ„¢ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.&lt;/p&gt; &lt;p&gt;All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.&lt;/p&gt; &lt;p&gt;Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the NQMC Inclusion Criteria which may be found at &lt;a href=&quot;../about/inclusion-criteria.aspx&quot;&gt;http://www.qualitymeasures.ahrq.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &lt;p&gt;Readers with questions regarding measure content are directed to contact the measure developer.&lt;/p&gt;" /></Field></Section></Version>
